NCCN Announces Selected Projects to Study Neratinib in Collaboration with Puma Biotechnology, Inc.
Research projects will explore the role of neratinib in gastric and gastroesophageal cancers as well as neurofibromatosis 2.
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced three research projects that have been selected for funding to evaluate neratinib in various tumor types. Neratinib is a type of tyrosine kinase inhibitor (TKI) that works as a dual inhibitor of the epidermal growth factor receptor 1 (EGFR) and human epidermal growth factor receptor 2 (HER2). The research is supported by a grant from Puma Biotechnology, Inc.
"These projects will add to our understanding of the optimal ways to target this pathway and further the management of these diseases, which include rare conditions," said Crystal S. Denlinger, MD, FACP, Senior Vice President, Chief Scientific Officer, NCCN. "We congratulate these impressive investigators and look forward to their findings."
The selected projects are:
Rutika Mehta, MD, MPH, Moffitt Cancer Center
Phase 2 study of neratinib in combination with chemotherapy and trastuzumab in HER2 overexpressing gastroesophageal cancers
Scott Plotkin, MD, PhD, Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center
Phase 2 study of neratinib for adolescents and adults with neurofibromatosis 2 and progressive NF2-related neoplasms: a sub-study of the INTUITT-NF2 platform-basket trial (NCT04374305)
Namrata Vijayvergia, MD, Fox Chase Cancer Center
Multi-center Phase 1 trial of neratinib and fam-trastuzumab deruxtecan in advanced refractory gastric cancer patients
Alan H. Auerbach, Chief Executive Officer and President of Puma Biotechnology, said, "We are pleased to support our partnership with the National Comprehensive Cancer Network in advancing cancer research and we congratulate the selected investigators. We are committed to exploring the efficacy of neratinib in a diverse range of tumor types for the benefit of affected patient populations and we look forward to the insights provided by these studies."
Proposals were peer reviewed by a Scientific Review Committee, which consisted of leading expert medical oncologists from NCCN Member Institutions. The funded concepts were selected based on several criteria, including scientific merit, existing data, feasibility and the types of studies needed to further evaluate neratinib. The research projects will commence late 2021 and take place over two years. The NCCN ORP will provide oversight. Puma is providing $1.4 million in funding and will also supply the neratinib tablets for use in the studies.
The NCCN ORP fosters innovation and knowledge discovery that improves the lives of people with cancer and supports preclinical, translational, and clinical research and quality improvement projects in oncology at NCCN Member Institutions. In an effort to improve collaboration in cancer research, the NCCN ORP also maintains a shared resources website and an informed consent database. For more information, visit NCCN.org/orp.
About the National Comprehensive Cancer Network The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based, expert consensus recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information and follow NCCN on Facebook @NCCNorg, Instagram @NCCNorg, and Twitter @NCCN. Media Contact: Rachel Darwin 267-622-6624 email@example.com SOURCE National Comprehensive Cancer Network